Abstract 342P
Background
This study aimed to assess breast cancer (BC) patients' knowledge and perception of fertility risks and preservation, and to determine factors that impact fertility preservation(FP) patient decision making.
Methods
We performed a cross-sectional study including 70 BC patients ≤ 45 year-old. Patients were surveyed using a 29 item questionnaire assessing their personal experience and knowledge about fertility risks and FP treatments. A knowledge score (0-12) was calculated with 1 point awarded for each correct answer. Statistical associations between socio-demographic characteristics, personal experience and knowledge score were analyzed.
Results
Mean age was 34 year-old. Thirty-seven patients had a college degree and 80% were married. Previous pregnancy/live birth were reported in 77%/72% of patients. Twenty-seven percent of patients had prior contact with infertility. Fifty-five patients were informed about infertility risks related to BC treatment. Only 62.8% of patients received information about FP treatments. Thirty-five patients were referred to FP consultation of whom 12 patients received FP treatments. Embryos/oocytes freezing were the main used options. The main reasons for skipping FP treatments were lack of pregnancy desire (38.6%) and insufficient provided information (30%). “Complexity of FP procedure” and “fear of delaying cancer treatment” were reported in 8.6% and 4.3% of cases respectively. Mean knowledge score was 6(3 -11). Forty-six percent of patients believed that “FP treatment is related to an increased risk of cancer recurrence”. Only 61.4% of patients were aware that “freezed eggs remain available in the future whenever the patient is ready to use them”. Most of the patients (81.4%) were aware that having a spouse was not a prerequisite for FP treatment. Knowledge about FP treatments availability and costs was poor with more than half of patients overestimating costs and assuming the lack of FP treatment options. Only 60% of patients were aware of an operational legal framework for FP in Tunisia.
Conclusions
This study showed that FP baseline knowledge in BC patients is generally poor. Patient's access to clear and concise fertility information is the key for effective interventions for fertility preservation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
434P - Incidence and prognostic value of HER2-low expression metastatic breast cancer in Asian population: A 10-year retrospective study
Presenter: Thanate Dajsakdipon
Session: Poster session 03
435P - Phase II single arm study of durvalumab and olaparib (D+O) in heavily pretreated triple-negative breast cancer (TNBC) with or without germline BRCA mutation (gBRCAm)
Presenter: Takeo Fujii
Session: Poster session 03
436P - Preliminary results from a prospective study of inetetamab in combination with pyrotinib and utidelone for HER2-positive metastatic breast cancer (IPUtrial)
Presenter: Hui Cao
Session: Poster session 03
437P - Improving safety and convenience for breast cancer patients receiving CDK 4/6 inhibitor treatment via a telemedicine app
Presenter: Bela Mrinakova
Session: Poster session 03
438P - Phase I study of ZV0203, a first in class pertuzumab ADC, in patients with HER2+ advanced solid tumors
Presenter: Fengjuan Lin
Session: Poster session 03
439P - Testing HR+ / HER2- patients with advanced or metastatic breast cancer for identification of tissue mutations in the PIK3CA gene: Results of a national program by the Hellenic Society of Medical Oncology (HeSMO)
Presenter: Anastasios Boutis
Session: Poster session 03
440P - Palliative radiotherapy in metastatic breast cancer: Does molecular subtype predict patient response to radiotherapy?
Presenter: Meriem El Bessi
Session: Poster session 03
441P - Real-world efficacy of ribociclib (RIB) + aromatase inhibitor (AI)/fulvestrant (FUL) in subgroups of special interest: 5th interim analysis (IA) of the RIBANNA study
Presenter: Achim Woeckel
Session: Poster session 03
442P - Menopausal status may derive in different second-line treatment benefits in breast cancer patients that experienced disease progression with CDK4/6 inhibitors (SUMA-001)
Presenter: Federico Waisberg
Session: Poster session 03
443P - Efficacy and safety of CDK 4/6 inhibitors in patients with bone marrow-involved metastatic breast cancer
Presenter: Cengiz Karacin
Session: Poster session 03